International journal of heart failure最新文献_第2页

The Third Nationwide Korean Heart Failure III Registry (KorHF III): The Study Design Paper. 第三次全国性韩国心衰 III 登记（KorHF III）：研究设计文件。

International journal of heart failure Pub Date : 2024-04-01 DOI: 10.36628/ijhf.2024.0001

Minjae Yoon, Eung Ju Kim, Seong Woo Han, Seong-Mi Park, In-Cheol Kim, Myeong-Chan Cho, Hyo-Suk Ahn, Mi-Seung Shin, Seok Jae Hwang, Jin-Ok Jeong, Dong Heon Yang, Jae-Joong Kim, Jin Oh Choi, Hyun-Jai Cho, Byung-Su Yoo, Seok-Min Kang, Dong-Ju Choi

{"title":"The Third Nationwide Korean Heart Failure III Registry (KorHF III): The Study Design Paper.","authors":"Minjae Yoon, Eung Ju Kim, Seong Woo Han, Seong-Mi Park, In-Cheol Kim, Myeong-Chan Cho, Hyo-Suk Ahn, Mi-Seung Shin, Seok Jae Hwang, Jin-Ok Jeong, Dong Heon Yang, Jae-Joong Kim, Jin Oh Choi, Hyun-Jai Cho, Byung-Su Yoo, Seok-Min Kang, Dong-Ju Choi","doi":"10.36628/ijhf.2024.0001","DOIUrl":"https://doi.org/10.36628/ijhf.2024.0001","url":null,"abstract":"With advancements in both pharmacologic and non-pharmacologic treatments, significant changes have occurred in heart failure (HF) management. The previous Korean HF registries, namely the Korea Heart Failure Registry (KorHF-registry) and Korean Acute Heart Failure Registry (KorAHF-registry), no longer accurately reflect contemporary acute heart failure (AHF) patients. Our objective is to assess contemporary AHF patients through a nationwide registry encompassing various aspects, such as clinical characteristics, management approaches, hospital course, and long-term outcomes of individuals hospitalized for AHF in Korea. This prospective observational multicenter cohort study (KorHF III) is organized by the Korean Society of Heart Failure. We aim to prospectively enroll 7,000 or more patients hospitalized for AHF at 47 tertiary hospitals in Korea starting from March 2018. Eligible patients exhibit signs and symptoms of HF and demonstrate either lung congestion or objective evidence of structural or functional cardiac abnormalities in echocardiography, or isolated right-sided HF. Patients will be followed up for up to 5 years after enrollment in the registry to evaluate long-term clinical outcomes. KorHF III represents the nationwide AHF registry that will elucidate the clinical characteristics, management strategies, and outcomes of contemporary AHF patients in Korea.Trial registration: ClinicalTrials.gov Identifier: NCT04329234.","PeriodicalId":101410,"journal":{"name":"International journal of heart failure","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11058439/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140872993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Precision Cardiology: Phenotype-targeted Therapies for HFmrEF and HFpEF. 精准心脏病学：针对 HFmrEF 和 HFpEF 的表型靶向疗法。

International journal of heart failure Pub Date : 2024-03-25 eCollection Date: 2024-04-01 DOI: 10.36628/ijhf.2023.0058

Giuseppe M C Rosano, Cristiana Vitale, Ilaria Spoletini

引用次数: 0

Is It Time to Expand the Indication of DOAC to Patients With Cardiac Amyloidosis and Atrial Fibrillation? 是时候将 DOAC 的适应症扩展至心脏淀粉样变性和心房颤动患者了吗？

International journal of heart failure Pub Date : 2024-01-22 eCollection Date: 2024-01-01 DOI: 10.36628/ijhf.2024.0002

So-Ryoung Lee, Jung-Min Choi

引用次数: 0

What Is the Right Direction for the IJHF and Editorial Board? IJHF 和编辑委员会的正确方向是什么？

International journal of heart failure Pub Date : 2024-01-18 eCollection Date: 2024-01-01 DOI: 10.36628/ijhf.2024.0005

Seong-Mi Park

引用次数: 0

The Relationship Between C-reactive Protein and Takotsubo Syndrome: An Old Riddle. C 反应蛋白与塔克次氏综合征的关系：一个古老的谜团

International journal of heart failure Pub Date : 2024-01-03 eCollection Date: 2024-01-01 DOI: 10.36628/ijhf.2023.0063

Sunki Lee

引用次数: 0

Application and Potential of Artificial Intelligence in Heart Failure: Past, Present, and Future. 人工智能在心力衰竭中的应用和潜力：过去、现在和未来。

International journal of heart failure Pub Date : 2023-11-30 eCollection Date: 2024-01-01 DOI: 10.36628/ijhf.2023.0050

Minjae Yoon, Jin Joo Park, Taeho Hur, Cam-Hao Hua, Musarrat Hussain, Sungyoung Lee, Dong-Ju Choi

{"title":"Application and Potential of Artificial Intelligence in Heart Failure: Past, Present, and Future.","authors":"Minjae Yoon, Jin Joo Park, Taeho Hur, Cam-Hao Hua, Musarrat Hussain, Sungyoung Lee, Dong-Ju Choi","doi":"10.36628/ijhf.2023.0050","DOIUrl":"https://doi.org/10.36628/ijhf.2023.0050","url":null,"abstract":"The prevalence of heart failure (HF) is increasing, necessitating accurate diagnosis and tailored treatment. The accumulation of clinical information from patients with HF generates big data, which poses challenges for traditional analytical methods. To address this, big data approaches and artificial intelligence (AI) have been developed that can effectively predict future observations and outcomes, enabling precise diagnoses and personalized treatments of patients with HF. Machine learning (ML) is a subfield of AI that allows computers to analyze data, find patterns, and make predictions without explicit instructions. ML can be supervised, unsupervised, or semi-supervised. Deep learning is a branch of ML that uses artificial neural networks with multiple layers to find complex patterns. These AI technologies have shown significant potential in various aspects of HF research, including diagnosis, outcome prediction, classification of HF phenotypes, and optimization of treatment strategies. In addition, integrating multiple data sources, such as electrocardiography, electronic health records, and imaging data, can enhance the diagnostic accuracy of AI algorithms. Currently, wearable devices and remote monitoring aided by AI enable the earlier detection of HF and improved patient care. This review focuses on the rationale behind utilizing AI in HF and explores its various applications.","PeriodicalId":101410,"journal":{"name":"International journal of heart failure","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10827704/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139673985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Optimizing Heart Failure Management: A Review of the Clinical Pharmacist Integration to the Multidisciplinary Health Care Team. 优化心力衰竭管理：临床药剂师融入多学科医疗团队的回顾。

International journal of heart failure Pub Date : 2023-11-15 eCollection Date: 2024-01-01 DOI: 10.36628/ijhf.2023.0022

Esteban Zavaleta-Monestel, Sebastián Arguedas-Chacón, Alonso Quirós-Romero, José Miguel Chaverri-Fernández, Bruno Serrano-Arias, José Pablo Díaz-Madriz, Jonathan García-Montero, Mario Osvaldo Speranza-Sanchez

{"title":"Optimizing Heart Failure Management: A Review of the Clinical Pharmacist Integration to the Multidisciplinary Health Care Team.","authors":"Esteban Zavaleta-Monestel, Sebastián Arguedas-Chacón, Alonso Quirós-Romero, José Miguel Chaverri-Fernández, Bruno Serrano-Arias, José Pablo Díaz-Madriz, Jonathan García-Montero, Mario Osvaldo Speranza-Sanchez","doi":"10.36628/ijhf.2023.0022","DOIUrl":"https://doi.org/10.36628/ijhf.2023.0022","url":null,"abstract":"Heart failure (HF) stands as a prevalent chronic ailment, imposing a substantial burden on global healthcare systems due to recurrent hospitalizations, intricate management, persistent symptoms, and polypharmacy challenges. The augmentation of patient safety and treatment efficacy across various care stages, facilitated by a multidisciplinary HF team inclusive of a clinical pharmacist, emerges as paramount. Evidence underscores that the collaborative engagement of a physician and a clinical pharmacist engenders proficient and secure management, forestalling avoidable adversities stemming from drug reactions and prescription inaccuracies. This synergistic approach tailors treatments optimally to individual patients. Post-discharge, the vulnerability of HF patients to re-hospitalization looms large, historically holding sway as the foremost cause of 30-day readmissions. Diverse strategies have been instituted to fortify patient well-being, leading to the formulation of specialized transitional care programs that shepherd patients effectively from hospital to outpatient settings. These initiatives have demonstrably curtailed readmission rates. This review outlines a spectrum of roles assumed by clinical pharmacists within the healthcare cohort, spanning inpatient care, transitional phases, and outpatient services. Moreover, it traverses a compendium of studies spotlighting the affirmative impact instigated by integrating clinical pharmacists into these fields.","PeriodicalId":101410,"journal":{"name":"International journal of heart failure","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10827703/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139674023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Vitamin D Deficiency in Patients Hospitalized for Heart Failure Living in the Tropics. 热带地区心力衰竭住院病人的维生素 D 缺乏症。

International journal of heart failure Pub Date : 2023-11-14 eCollection Date: 2024-04-01 DOI: 10.36628/ijhf.2023.0025

Lucian Batista de Oliveira, Mariana Andrade de Figueiredo Martins Siqueira, Rafael Buarque de Macedo Gadêlha, Jessica Garcia, Francisco Bandeira

{"title":"Vitamin D Deficiency in Patients Hospitalized for Heart Failure Living in the Tropics.","authors":"Lucian Batista de Oliveira, Mariana Andrade de Figueiredo Martins Siqueira, Rafael Buarque de Macedo Gadêlha, Jessica Garcia, Francisco Bandeira","doi":"10.36628/ijhf.2023.0025","DOIUrl":"https://doi.org/10.36628/ijhf.2023.0025","url":null,"abstract":"Background and objectives: Vitamin D, as a steroid hormone, has multiple effects on human body and its deficiency has been associated with an increased risk of heart failure (HF) and unfavorable outcomes. The present study investigated the prevalence of vitamin D deficiency (VDD) and its relationship with cardiometabolic parameters in patients hospitalized for HF living in the city of Recife (latitude 8° South).Methods: Analytical cross-sectional study, with men and women aged 40-64 years. The HF group was recruited during hospitalization due to decompensation. A matched control group was recruited from the general endocrine clinics. Vitamin D status was assessed by measuring serum 25-hydroxyvitamin D (25OHD), considering deficiency when 25OHD <20 ng/mL (<50 nmol/L).Results: A total of 243 patients were evaluated (HF group: 161, control group: 82). Lower serum 25OHD levels were observed in the HF group (25.2±9.4 vs. 30.0±7.7ng/mL; p<0.001), as well as a higher prevalence of VDD (27.3% vs. 9.8%; prevalence ratio, 2.80; 95% confidence interval, 1.38-5.67; p=0.002). In patients with HF, VDD was associated with diabetes mellitus (65.9% vs. 41.0%; p=0.005) and female sex (65.9% vs. 44.4%; p=0.015). In the subgroup with VDD, higher values of hemoglobin A1c (7.9% [6.0-8.9] vs. 6.2% [5.7-7.9]; p=0.006) and dyslipidemia were also observed.Conclusions: We found higher rates of VDD in patients hospitalized for HF and this was associated with deleterious laboratory metabolic parameters.","PeriodicalId":101410,"journal":{"name":"International journal of heart failure","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11058433/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140855013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Iron Deficiency in Heart Failure: A Korea-Oriented Review. 心力衰竭中的缺铁：以韩国为导向的综述。

International journal of heart failure Pub Date : 2023-10-25 eCollection Date: 2023-10-01 DOI: 10.36628/ijhf.2023.0032

Ewa A Jankowska, Piotr Ponikowski

{"title":"Iron Deficiency in Heart Failure: A Korea-Oriented Review.","authors":"Ewa A Jankowska, Piotr Ponikowski","doi":"10.36628/ijhf.2023.0032","DOIUrl":"10.36628/ijhf.2023.0032","url":null,"abstract":"Iron deficiency (ID) occurs at high frequency across the spectrum of heart failure (HF), with HF severity and race being potentially important predictors for its development. ID, irrespective of anaemia status, leads to poor outcomes in patients with HF, including exacerbated reduction in exercise capacity, poor quality of life (QoL) and increased risk of HF hospitalisation. As ID has a large public health and economic burden in Asia, and patients hospitalised with acute HF in the Asia Pacific vs. other regions commonly present with more severe clinical symptoms, there is a clear need to identify and treat ID promptly in Asian patients with HF. The biomarkers serum ferritin and transferrin saturation are used for ID diagnosis, and periodic screening is recommended in all patients with HF. The intravenous iron treatments, ferric carboxymaltose (FCM) and ferric derisomaltose, have demonstrated efficacy and tolerability in patients with acute or chronic HF and ID, with FCM shown to be cost-effective (and in some cases cost-saving). Meta-analyses support the likely benefits of intravenous FCM for improving QoL and reducing HF hospitalisation, without reducing mortality risk in patients with HF and ID. Accordingly, European Society of Cardiology guidelines recommend considering intravenous FCM for patients with symptomatic HF with left ventricular ejection fraction ≤50% who were recently hospitalised for HF and have ID. Although analyses of Asian patients with HF and ID are limited, the effects of intravenous iron would be expected to be similar to that in White populations; further clarifying studies may be of interest.","PeriodicalId":101410,"journal":{"name":"International journal of heart failure","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10625879/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71490983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Novel Insights Into the Pathogenesis of Obesity-Related High Output Heart Failure From Gene Expression Profiling. 从基因表达谱对肥胖相关高输出量心力衰竭发病机制的新见解。

International journal of heart failure Pub Date : 2023-10-25 eCollection Date: 2023-10-01 DOI: 10.36628/ijhf.2023.0048

Huijin Lee, Hyun-Jai Cho

引用次数: 0